Beschreibung
Cyclosporine, a strong dual inhibitor of CYP3A4 and P-glycoprotein, substantially increases rivaroxaban exposure and bleeding risk.
Mechanismus
Rivaroxaban depends on CYP3A4 for metabolism and P-gp for intestinal efflux; cyclosporine inhibits both, increasing rivaroxaban AUC by up to 50%.
Klinische Bedeutung
This combination is generally contraindicated in post-transplant patients who may also have organ-specific bleeding risks.
Maßnahmen
Avoid combination; consider alternative anticoagulation strategies in transplant recipients requiring anticoagulation.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.